Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broad Effectiveness Trial with Aripiprazole (BETA)
NCT00036361Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2002
- Primary completion
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in schizophrenia and schizoaffective disorder comparing Aripiprazole with Standard of Care (2 arms). Primary endpoints: Clinical Global Impression - Improvement at 8 weeks and Safety Assessments. Started Jul 2002; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00036361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036361.